Preparing to tackle big markets
Immunovia | 07/12/2017

Immunovia continues to leverage the IMMray technology to additional opportunities with prospective trials in the group of early pancreatic cancer symptoms…

New opportunities in sight as first sales approach
Immunovia | 02/10/2017

Immunovia is on track to start commercialising its PanCan-d test for the early detection of pancreatic cancer in high-risk patients in 2018. To this end,…

Final top-line IMMray data in Lupus, FY16 results
Immunovia | 30/03/2017

Immunovia has announced final top-line data of the IMMray platform from a retrospective study in autoimmune diseases. The study showed that the IMMray…